BOSTON – Consumer genomics firm 23andMe has partnered with PatientsLikeMe, a company that facilitates the sharing of patient outcomes data, to conduct research on Parkinson's disease.

With access to PatientsLikeMe's community-based patient groups and its platform for collecting and sharing outcomes data, 23andMe plans to recruit 10,000 people for a large study on Parkinson's disease. The goal of 23andMe's Parkinson's disease study is to identify the genetic and environmental factors for the disease, as well as gauge the effectiveness of different treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.